Tag: TG4050
Transgene: positive results for TG4050 in head and neck cancer
(AOF) – Transgene and NEC presented the first signs of clinical benefit of their individualized cancer vaccine, TG4050, in head and neck cancers at the annual meeting of the American…
Transgene and NEC Corporation continue clinical development of TG4050
By Olivier Cheilan Published on 01/08/2024 at 5:58 p.m. (Boursier.com) — Transgene and NEC Corporation announced the signing…
Transgene presented new Phase I data of TG4050 at the ASCO 2022 congress – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8 a.m. – Transgene (Euronext Paris: TNG), a biotechnology company that designs and develops immunotherapies based on viral vectors against cancers, announces that it has…
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 – 06/06/2022 at 08:00
Strasbourg, France, June 6, 2022, 8:00 am CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that…
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 – 04/08/2022 at 19:00
Transgene will discuss new immunogenicity and clinical data generated with TG4050 that reinforce the strong potential of this individualized immunotherapy:o Relevant neoantigens could be identified in all evaluable patients and…
Transgene presents new preliminary Phase I data confirming the potential of TG4050 at the AACR 2022 congress – 04/08/2022 at 19:00
Transgene presents new clinical and immunogenicity data for TG4050 that confirm the significant potential of this individualized immunotherapy:o In all evaluable patients, target neoantigens could be identified; TG4050 induced specific…